Does the media prefer BMRN or RVMD?

In the previous week, Revolution Medicines had 2 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 9 mentions for Revolution Medicines and 7 mentions for BioMarin Pharmaceutical. Revolution Medicines' average media sentiment score of 0.38 beat BioMarin Pharmaceutical's score of 0.24 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Revolution Medicines 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BMRN or BIIB?

In the previous week, Biogen had 8 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 15 mentions for Biogen and 7 mentions for BioMarin Pharmaceutical. Biogen's average media sentiment score of 0.48 beat BioMarin Pharmaceutical's score of 0.24 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biogen 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor ALNY or BMRN?

In the previous week, Alnylam Pharmaceuticals had 12 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 19 mentions for Alnylam Pharmaceuticals and 7 mentions for BioMarin Pharmaceutical. Alnylam Pharmaceuticals' average media sentiment score of 0.35 beat BioMarin Pharmaceutical's score of 0.24 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral BioMarin Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ROIV or BMRN?

In the previous week, Roivant Sciences had 2 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 9 mentions for Roivant Sciences and 7 mentions for BioMarin Pharmaceutical. Roivant Sciences' average media sentiment score of 0.83 beat BioMarin Pharmaceutical's score of 0.24 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BNTX or BMRN?

In the previous week, BioNTech had 22 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 29 mentions for BioNTech and 7 mentions for BioMarin Pharmaceutical. BioNTech's average media sentiment score of 0.52 beat BioMarin Pharmaceutical's score of 0.24 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 11 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

BioMarin Pharmaceutical (BMRN) Competitors

$54.79 -0.10 (-0.18%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$55.06 +0.27 (+0.50%)

As of 10/9/2026 07:54 PM Eastern

Compare

BMRN vs. RVMD, BIIB, ALNY, ROIV, and BNTX

Should you buy BioMarin Pharmaceutical stock or one of its competitors? BioMarin Pharmaceutical's main competitors and comparable companies include Revolution Medicines (RVMD), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Roivant Sciences (ROIV), and BioNTech (BNTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioMarin Pharmaceutical compare to Revolution Medicines?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

BioMarin Pharmaceutical presently has a consensus price target of $87.82, suggesting a potential upside of 60.28%. Revolution Medicines has a consensus price target of $234.76, suggesting a potential upside of 23.72%. Given BioMarin Pharmaceutical's higher possible upside, equities research analysts plainly believe BioMarin Pharmaceutical is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	7 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.65
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, Revolution Medicines had 2 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 9 mentions for Revolution Medicines and 7 mentions for BioMarin Pharmaceutical. Revolution Medicines' average media sentiment score of 0.38 beat BioMarin Pharmaceutical's score of 0.24 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revolution Medicines	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioMarin Pharmaceutical has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Revolution Medicines' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Revolution Medicines	N/A	-88.20%	-57.85%

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BioMarin Pharmaceutical has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.29	$348.90M	$0.37	148.08
Revolution Medicines	$11.58M	3,512.36	-$1.13B	-$8.82	N/A

Summary

BioMarin Pharmaceutical beats Revolution Medicines on 9 of the 16 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to Biogen?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

BioMarin Pharmaceutical presently has a consensus price target of $87.82, suggesting a potential upside of 60.28%. Biogen has a consensus price target of $231.07, suggesting a potential upside of 2.38%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	7 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.65
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56

BioMarin Pharmaceutical has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, Biogen has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

Biogen has a net margin of 8.32% compared to BioMarin Pharmaceutical's net margin of 2.14%. Biogen's return on equity of 11.18% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Biogen	8.32%	11.18%	6.88%

In the previous week, Biogen had 8 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 15 mentions for Biogen and 7 mentions for BioMarin Pharmaceutical. Biogen's average media sentiment score of 0.48 beat BioMarin Pharmaceutical's score of 0.24 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biogen	5 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Biogen has higher revenue and earnings than BioMarin Pharmaceutical. Biogen is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.29	$348.90M	$0.37	148.08
Biogen	$9.89B	3.37	$1.29B	$5.65	39.95

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Biogen beats BioMarin Pharmaceutical on 10 of the 16 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Alnylam Pharmaceuticals presently has a consensus target price of $366.65, suggesting a potential upside of 57.58%. BioMarin Pharmaceutical has a consensus target price of $87.82, suggesting a potential upside of 60.28%. Given BioMarin Pharmaceutical's higher probable upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Alnylam Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88
BioMarin Pharmaceutical	1 Sell rating(s)	7 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.65

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Alnylam Pharmaceuticals has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market.

BioMarin Pharmaceutical has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.38	$313.75M	$5.38	43.25
BioMarin Pharmaceutical	$3.22B	3.29	$348.90M	$0.37	148.08

In the previous week, Alnylam Pharmaceuticals had 12 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 19 mentions for Alnylam Pharmaceuticals and 7 mentions for BioMarin Pharmaceutical. Alnylam Pharmaceuticals' average media sentiment score of 0.35 beat BioMarin Pharmaceutical's score of 0.24 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioMarin Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alnylam Pharmaceuticals has a net margin of 15.26% compared to BioMarin Pharmaceutical's net margin of 2.14%. Alnylam Pharmaceuticals' return on equity of 84.93% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

Summary

Alnylam Pharmaceuticals beats BioMarin Pharmaceutical on 13 of the 17 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Roivant Sciences presently has a consensus target price of $45.64, suggesting a potential upside of 28.77%. BioMarin Pharmaceutical has a consensus target price of $87.82, suggesting a potential upside of 60.28%. Given BioMarin Pharmaceutical's higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
BioMarin Pharmaceutical	1 Sell rating(s)	7 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.65

In the previous week, Roivant Sciences had 2 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 9 mentions for Roivant Sciences and 7 mentions for BioMarin Pharmaceutical. Roivant Sciences' average media sentiment score of 0.83 beat BioMarin Pharmaceutical's score of 0.24 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioMarin Pharmaceutical has a net margin of 2.14% compared to Roivant Sciences' net margin of -3,534.96%. BioMarin Pharmaceutical's return on equity of 5.32% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

BioMarin Pharmaceutical has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,099.16	-$299.77M	-$0.53	N/A
BioMarin Pharmaceutical	$3.22B	3.29	$348.90M	$0.37	148.08

Roivant Sciences has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market.

Summary

BioMarin Pharmaceutical beats Roivant Sciences on 10 of the 16 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to BioNTech?

BioNTech (NASDAQ:BNTX) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

BioNTech has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market.

BioNTech presently has a consensus target price of $125.69, suggesting a potential upside of 29.63%. BioMarin Pharmaceutical has a consensus target price of $87.82, suggesting a potential upside of 60.28%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	6 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.65
BioMarin Pharmaceutical	1 Sell rating(s)	7 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.65

BioMarin Pharmaceutical has a net margin of 2.14% compared to BioNTech's net margin of -63.54%. BioMarin Pharmaceutical's return on equity of 5.32% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BioMarin Pharmaceutical has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.55	-$1.29B	-$7.83	N/A
BioMarin Pharmaceutical	$3.22B	3.29	$348.90M	$0.37	148.08

In the previous week, BioNTech had 22 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 29 mentions for BioNTech and 7 mentions for BioMarin Pharmaceutical. BioNTech's average media sentiment score of 0.52 beat BioMarin Pharmaceutical's score of 0.24 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	11 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BioMarin Pharmaceutical beats BioNTech on 10 of the 16 factors compared between the two stocks.

Get BioMarin Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMRN vs. The Competition

Export

Metric	BioMarin Pharmaceutical	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.61B	$3.93B	$7.25B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	148.08	13.62	275.29	26.14
Price / Sales	3.29	1,209.42	576.46	85.31
Price / Cash	19.20	119.49	76.96	53.71
Price / Book	1.73	17.17	11.22	6.33
Net Income	$348.90M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-4.18%	-1.34%	-0.89%	-1.40%
1 Month Performance	-16.58%	-8.04%	-4.02%	-3.35%
1 Year Performance	4.72%	14.18%	7.13%	1.49%

BioMarin Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMRN BioMarin Pharmaceutical	4.1998 of 5 stars	$54.79 -0.2%	$87.82 +60.3%	+4.7%	$10.61B	$3.22B	148.08	3,221
RVMD Revolution Medicines	3.0193 of 5 stars	$206.93 +0.5%	$234.33 +13.2%	+293.4%	$44.30B	$11.58M	N/A	883	Analyst Forecast
BIIB Biogen	3.0343 of 5 stars	$220.74 -0.9%	$230.14 +4.3%	+54.0%	$32.61B	$9.89B	39.06	7,500	Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.4291 of 5 stars	$222.73 -3.7%	$366.90 +64.7%	-49.4%	$29.85B	$3.71B	41.46	2,770	News Coverage Analyst Forecast Insider Trade
ROIV Roivant Sciences	2.7487 of 5 stars	$35.80 +0.8%	$45.64 +27.5%	+120.9%	$25.85B	$8.26M	N/A	721

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BMRN) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioMarin Pharmaceutical (BMRN) Competitors

BMRN vs. RVMD, BIIB, ALNY, ROIV, and BNTX

How does BioMarin Pharmaceutical compare to Revolution Medicines?

Summary

How does BioMarin Pharmaceutical compare to Biogen?

Summary

How does BioMarin Pharmaceutical compare to Alnylam Pharmaceuticals?

Summary

How does BioMarin Pharmaceutical compare to Roivant Sciences?

Summary

How does BioMarin Pharmaceutical compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRN vs. The Competition

BioMarin Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioMarin Pharmaceutical (BMRN) Competitors

BMRN vs. RVMD, BIIB, ALNY, ROIV, and BNTX

How does BioMarin Pharmaceutical compare to Revolution Medicines?

Do analysts rate BMRN or RVMD?

Does the media prefer BMRN or RVMD?

Which has more risk & volatility, BMRN or RVMD?

Is BMRN or RVMD more profitable?

Do institutionals & insiders hold more shares of BMRN or RVMD?

Which has higher earnings & valuation, BMRN or RVMD?

Summary

How does BioMarin Pharmaceutical compare to Biogen?

Do analysts rate BMRN or BIIB?

Which has more risk & volatility, BMRN or BIIB?

Is BMRN or BIIB more profitable?

Does the media refer more to BMRN or BIIB?

Which has stronger valuation & earnings, BMRN or BIIB?

Do institutionals & insiders hold more shares of BMRN or BIIB?

Summary

How does BioMarin Pharmaceutical compare to Alnylam Pharmaceuticals?

Do analysts prefer ALNY or BMRN?

Do institutionals & insiders have more ownership in ALNY or BMRN?

Which has more volatility & risk, ALNY or BMRN?

Which has stronger earnings & valuation, ALNY or BMRN?

Does the media favor ALNY or BMRN?

Is ALNY or BMRN more profitable?

Summary

How does BioMarin Pharmaceutical compare to Roivant Sciences?

Do institutionals and insiders hold more shares of ROIV or BMRN?

Do analysts rate ROIV or BMRN?

Does the media prefer ROIV or BMRN?

Is ROIV or BMRN more profitable?

Which has higher valuation & earnings, ROIV or BMRN?

Which has more risk and volatility, ROIV or BMRN?

Summary

How does BioMarin Pharmaceutical compare to BioNTech?

Which has more risk and volatility, BNTX or BMRN?

Do analysts prefer BNTX or BMRN?

Is BNTX or BMRN more profitable?

Do institutionals & insiders have more ownership in BNTX or BMRN?

Which has preferable valuation & earnings, BNTX or BMRN?

Does the media prefer BNTX or BMRN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRN vs. The Competition

BioMarin Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools